Drugs / rhCC10
rhCC10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01473264 | Jan 2000 → Jun 2002 | bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | Clarassance, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01941745 | Oct 2013 → Aug 2017 | bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | Tufts Medical Center | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhCC10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01941745 ↗ |
| Known as | recombinant human CC10 | “The safety, pharmacokinetics, and anti-inflammatory activity of recombinant human CC10 (rhCC10) were evaluated in a randomized, placebo-controlled, double-blinded, multicenter trial” PMID 15774846 ↗ Mar 2005 |
| Known as | recombinant human CC10 protein | “Recombinant human CC10 protein (rhCC10) is a novel therapeutic agent used to prevent the development of chronic respiratory morbidity (CPIP; repeated respiratory infections,...” NCT01941745 ↗ |
| Known as | Recombinant Human Clara Cell 10 Protein | “Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome” NCT01941745 ↗ |
| Known as | Recombinant Human Clara Cell Protein | “Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome” NCT01941745 ↗ |
| Modality | Protein / enzyme biologic | “The study drug, rhCC10, is a recombinant version of natural human CC10 protein.” NCT01473264 ↗ |
| Route | Other | “single intratracheal (IT) dose of rhCC10” NCT01473264 ↗ |